CKD Prevalence Varies across the European General Population

Katharina Brück(European Hematology Association), Vianda S Stel(European Hematology Association), Giovanni Gambaro(Università Cattolica del Sacro Cuore), Stein Hallan(Norwegian University of Science and Technology), Henry Völzke(Universitätsmedizin Greifswald), Johan Ärnlöv(Uppsala University), Mika Kastarinen(Finnish Medicines Agency Fimea), Idris Guessous(University Hospital of Geneva), José Vinhas(Hospital de São Bernardo), Bénédicte Stengel(Inserm), Hermann Brenner(German Cancer Research Center), Jerzy Chudek(Medical University of Silesia), Solfrid Romundstad(Norwegian University of Science and Technology), Charles Tomson(Freeman Hospital), Alfonso Otero González, Aminu K. Bello(University of Alberta), Jean Ferrières(Hôpital Rangueil), Luigi Palmieri(Istituto Superiore di Sanità), Gemma Browne(University College Cork), Vincenzo Capuano, Wim Van Biesen(Ghent University Hospital), Carmine Zoccali(Istituto di Fisiologia Clinica), Ron T. Gansevoort, Gerjan Navis(University Medical Center Groningen), Dietrich Rothenbacher(Universität Ulm), Pietro Manuel Ferraro(Università Cattolica del Sacro Cuore), Dorothea Nitsch(London School of Hygiene & Tropical Medicine), Christoph Wanner(Universitätsklinikum Würzburg), Kitty J. Jager(European Hematology Association)
Journal of the American Society of Nephrology
December 23, 2015
Cited by 585Open Access
Full Text

Abstract

CKD prevalence estimation is central to CKD management and prevention planning at the population level. This study estimated CKD prevalence in the European adult general population and investigated international variation in CKD prevalence by age, sex, and presence of diabetes, hypertension, and obesity. We collected data from 19 general-population studies from 13 European countries. CKD stages 1-5 was defined as eGFR<60 ml/min per 1.73 m(2), as calculated by the CKD-Epidemiology Collaboration equation, or albuminuria >30 mg/g, and CKD stages 3-5 was defined as eGFR<60 ml/min per 1.73 m(2) CKD prevalence was age- and sex-standardized to the population of the 27 Member States of the European Union (EU27). We found considerable differences in both CKD stages 1-5 and CKD stages 3-5 prevalence across European study populations. The adjusted CKD stages 1-5 prevalence varied between 3.31% (95% confidence interval [95% CI], 3.30% to 3.33%) in Norway and 17.3% (95% CI, 16.5% to 18.1%) in northeast Germany. The adjusted CKD stages 3-5 prevalence varied between 1.0% (95% CI, 0.7% to 1.3%) in central Italy and 5.9% (95% CI, 5.2% to 6.6%) in northeast Germany. The variation in CKD prevalence stratified by diabetes, hypertension, and obesity status followed the same pattern as the overall prevalence. In conclusion, this large-scale attempt to carefully characterize CKD prevalence in Europe identified substantial variation in CKD prevalence that appears to be due to factors other than the prevalence of diabetes, hypertension, and obesity.


Related Papers

No related papers found

Powered by citation graph analysis